{{medical}}

'''抗CD3[[单克隆抗体|单克隆抗体]]'''（{{lang|en|Anti-CD3 Monoclonal antibody}}），是一类[[T细胞|T细胞]]表面CD3的抗体，他们是一类[[免疫功能抑制药物|免疫功能抑制药物]]。


1996年，首批获得批准的药物是[[莫罗单抗-CD3|莫罗单抗-CD3]]，其用于治疗[[移植排斥|移植排斥]]。

更新的单克隆抗体具有相同的作用机制，产品包括有{{le|otelixizumab|otelixizumab}}、{{le|Teplizumab|Teplizumab}}和{{le|Visilizumab|Visilizumab}}。这些药物用于治疗如[[克罗恩病|克罗恩病]]、[[溃疡性结肠炎|溃疡性结肠炎]]和[[1型糖尿病|1型糖尿病]]等病变情况<ref>{{cite journal |title=Treatment of Type 1 diabetes with anti-CD3 monoclonal antibody: induction of immune regulation? |year=2003 |author=Herold KC, Taylor L. |pmid=14610290 |doi=10.1385/IR:28:2:141 |volume=28 |issue=2 |pages=141–50 |journal=Immunologic Research}}</ref>，以及进行诱导[[免疫耐受|免疫耐受]]<ref>{{cite journal |url=http://www.jci.org/articles/view/23961/version/1 |title=TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs |year=2005 |author=Bisikirska |display-authors=etal |access-date=2016-05-04 |archive-date=2019-12-06 |archive-url=https://web.archive.org/web/20191206172054/https://www.jci.org/articles/view/23961/version/1 |dead-url=no }}</ref><ref>{{cite journal |title=Use of Anti-CD3 Monoclonal Antibody to Induce Immune Regulation in Type 1 Diabetes |year=2004 |author=Bisikirska & Herold |doi=10.1196/annals.1337.001 |last2=Herold |first2=Kevan C. |journal=Annals of the New York Academy of Sciences |volume=1037 |pages=1–9 |pmid=15699486}}</ref>。

==相关==
* {{le|单克隆抗体列表|List of monoclonal antibodies}}

==参考==
{{reflist}}

[[Category:单克隆抗体类|Category:单克隆抗体类]]
[[Category:治疗用抗体|Category:治疗用抗体]]